WILLIAM PEACOCK to Warfarin
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Warfarin.
Connection Strength
1.170
-
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism? Clin Appl Thromb Hemost. 2017 Oct; 23(7):830-837.
Score: 0.515
-
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 08; 48(8):2142-2149.
Score: 0.137
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.133
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.130
-
Elevated international normalized ratio in the ED: clinical course and physician adherence to the published recommendations. Am J Emerg Med. 2005 Jan; 23(1):40-4.
Score: 0.058
-
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Am J Emerg Med. 2020 06; 38(6):1163-1170.
Score: 0.041
-
Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS One. 2017; 12(10):e0185022.
Score: 0.035
-
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 09; 33(9):1697-1703.
Score: 0.034
-
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul; 39(7):1426-1436.e2.
Score: 0.034
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.033
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
Score: 0.020